NCT07887750Not yet recruitingPhase 1/2
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
Phase 1 Trial to Investigate the Safety and Tolerability of REGN9220, an Anti-CD22 X Anti-4-1BB Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphomas
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
This study will test a new experimental study drug called REGN9220 with a Regeneron drug called odronextamab (both called "study drug") to see if it can help treat people with aggressive BCNHL that has either come back/gotten worse or has not responded to previous treatment. The study is looking at: * What side effects REGN9220 might cause when given with odronextamab * How well REGN9220 works when given with odronextamab * How much REGN9220 is in the blood at different times when given with odronextamab * If the body makes antibodies to REGN9220 when given with odronextamab, this may cause the REGN9220 to not work as well * How the body and immune system changes after having REGN9220 given with odronextamab, which can help researchers understand why REGN9220 given with odronextamab works better in some people than others * What is the best dose of REGN9220 when given with odronextamab
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 14 Oct 2026
- Start date
- 7 Dec 2026
- Primary completion date
- 1 Nov 2029
- Lead sponsor
- Regeneron Pharmaceuticals
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07887750
- EU CT number
- 2025-524780-20-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 36
- From 7 Dec 2026 to the primary completion date, 1 Nov 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with anti-CD20 x anti-CD3 bispecific antibody
Other illness
- Significant CNS disorders
- Active/uncontrolled infections
- Recent cancer therapy or major surgery
- Drug hypersensitivity
Other
- Diagnosis of Mantle Cell Lymphoma (MCL) or Central Nervous System (CNS) lymphoma
- Significant comorbidities
- Pregnancy/breastfeeding
- NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Who the study is looking for
- Documented Cluster of Differentiation (CD)20+ aggressive B-cell non-Hodgkin lymphoma that is relapsed or refractory
- Measurable disease on cross sectional imaging
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate organ function (hematologic, hepatic, and renal)
- Availability of tumor tissue for analysis for submission to central laboratory is required for trial enrollment
- Willingness to comply with contraception requirements and study procedures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.